Monte Rosa Therapeutics, Inc.GLUENASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank50
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-27.50M
↑ 26% vs avg
Percentile
P50
Within normal range
Streak
1 yr
Consecutive declineContracting
Average
$-37.26M
Historical baseline
PeriodValueYoY Change
TTM$-27.50M-172.3%
2024$38.01M+160.5%
2023$-62.84M+40.4%
2022$-105.38M-52.5%
2021$-69.09M-161.3%
2020$-26.44M-249.9%
2019$-7.56M-